ID   USPC-ARK-22
AC   CVCL_IV93
SY   USPC-ARK22; ARK22
DR   Wikidata; Q54991970
RX   PubMed=23891627;
RX   PubMed=25268372;
CC   Population: Caucasian.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
DI   NCIt; C27838; Endometrial serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 29-06-23; Version: 5
//
RX   PubMed=25268372; DOI=10.1038/bjc.2014.519; PMCID=PMC4453741;
RA   Schwab, Carlton L.
RA   Bellone, Stefania
RA   English, Diana P.
RA   Roque, Dana Marie
RA   Lopez, Salvatore
RA   Cocco, Emiliano
RA   Nicoletti, Roberta
RA   Bortolomai, Ileana
RA   Bonazzoli, Elena
RA   Ratner, Elena
RA   Silasi, Dan-Arin
RA   Azodi, Masoud
RA   Schwartz, Peter E.
RA   Rutherford, Thomas J.
RA   Santin, Alessandro D.
RT   "Afatinib demonstrates remarkable activity against HER2-amplified
RT   uterine serous endometrial cancer in vitro and in vivo.";
RL   Br. J. Cancer 111:1750-1756(2014).
//
RX   PubMed=23891627; DOI=10.1016/j.ajog.2013.07.020;
RA   English, Diana P.
RA   Bellone, Stefania
RA   Cocco, Emiliano
RA   Bortolomai, Ileana
RA   Pecorelli, Sergio
RA   Lopez, Salvatore
RA   Silasi, Dan-Arin
RA   Schwartz, Peter E.
RA   Rutherford, Thomas J.
RA   Santin, Alessandro D.
RT   "Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications
RT   determine the sensitivity of uterine serous carcinoma cell lines to
RT   GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase
RT   (TORC1/2).";
RL   Am. J. Obstet. Gynecol. 209:465.e1-465.e9(2013).
//